Non-Hodgkin Lymphoma | Specialty

Treating Relapsed/Refractory Follicular Lymphoma

January 18th 2016

First-Line Therapeutic Options in Follicular Lymphoma

January 18th 2016

'Watch and Wait' Versus Therapy Initiation in Follicular Lymphoma

January 18th 2016

Follicular Lymphoma Risk Stratification

January 18th 2016

The Biology of Follicular Lymphoma

January 18th 2016

Expert Discusses Emerging Agents and the Future of Follicular Lymphoma

January 18th 2016

John P. Leonard, MD, discusses the potential for lenalidomide, idelalisib, and ibrutinib in follicular lymphoma, possible combination therapies, and challenges that remain in the treatment of the disease.

Dr. Frederick Locke on KTE-C19 for Refractory NHL

January 13th 2016

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses KTE-C19 for the treatment of refractory aggressive non-Hodgkin lymphoma (NHL).

CAR T-Cell Therapy KTE-C19 Shows Promise in Non-Hodgkin Lymphoma

December 22nd 2015

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCL

December 22nd 2015

Adding brentuximab vedotin (Adcetris) to frontline R-CHOP produced a greater than 80% response rate—including complete remissions in three-fourths of patients—as a treatment for CD30+ diffuse large B-cell lymphoma.

Dr. Sharman on Entospletinib in Patients With CLL

December 18th 2015

Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Dr. Vlock on Anti—CD20 Interleukin-2 Immunocytokine in NHL

December 14th 2015

Daniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

FDA Approves Bendamustine Hydrochloride for CLL, NHL

December 9th 2015

The FDA has approved a rapid infusion formulation of bendamustine under the trade name Bendeka for the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLL

December 8th 2015

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Ibrutinib Active in Rituximab-Refractory WM

December 7th 2015

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Goy on Going Beyond R-CHOP in Large-Cell Lymphoma

November 19th 2015

Dr. Andre Goy discusses combining novel agents with R-CHOP for the treatment of large-cell lymphoma.

Dr. Leonard on Treatment Options for Patients With Indolent B-Cell NHL

November 16th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses therapies available for patients with indolent B-cell Non-Hodgkin lymphoma.

Genetics Should Dictate Treatment for Waldenström's Macroglobulinemia

November 3rd 2015

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström's macroglobulinemia.

Radiation Underutilized in Low-Grade Follicular Lymphoma

October 22nd 2015

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

October 20th 2015

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.